Literature DB >> 9743321

Chemokine regulation of experimental autoimmune encephalomyelitis: temporal and spatial expression patterns govern disease pathogenesis.

W J Karpus1, R M Ransohoff.   

Abstract

Experimental autoimmune encephalomyelitis (EAE) is a CD4+ Th1-mediated demyelinating disease of the central nervous system that serves as a model for multiple sclerosis (MS). There are several considerations that suggest a role for chemokines in the disease process. First, chemokines are highly expressed in the central nervous system with a tight temporal relationship to disease activity. Second, in vivo neutralization studies showed a distinct role for specific chemokines in the evolution of the process. Third, the selective and differential expression of chemokines in differing models of EAE bears a close relationship to the patterns of inflammatory pathology. Fourth, the spatial distribution of chemokine expression could plausibly contribute to lesion architecture. Finally, preliminary observations in MS material suggest that chemokine expression observed in EAE may provide useful information regarding the pathogenesis of inflammation in MS. We propose that temporal and spatial expression of chemokines are crucial factors, complementing adhesion molecule up-regulation, that regulate EAE disease activity.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9743321

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  57 in total

Review 1.  Unlinking tumor necrosis factor biology from the major histocompatibility complex: lessons from human genetics and animal models.

Authors:  S R Ruuls; J D Sedgwick
Journal:  Am J Hum Genet       Date:  1999-08       Impact factor: 11.025

Review 2.  Chemokines and central nervous system disorders.

Authors:  W J Karpus
Journal:  J Neurovirol       Date:  2001-12       Impact factor: 2.643

3.  Infection of non-encapsulated species of Trichinella ameliorates experimental autoimmune encephalomyelitis involving suppression of Th17 and Th1 response.

Authors:  Zhiliang Wu; Isao Nagano; Kazunobu Asano; Yuzo Takahashi
Journal:  Parasitol Res       Date:  2010-07-27       Impact factor: 2.289

4.  The role of MIP-1alpha in experimental hypersensitivity pneumonitis.

Authors:  M Schuyler; K Gott; V French
Journal:  Lung       Date:  2004       Impact factor: 2.584

Review 5.  Mechanisms and implications of adaptive immune responses after traumatic spinal cord injury.

Authors:  D P Ankeny; P G Popovich
Journal:  Neuroscience       Date:  2008-07-04       Impact factor: 3.590

6.  Inhibition of experimental autoimmune encephalomyelitis by a novel small molecular weight proinflammatory cytokine suppressing drug.

Authors:  William J Karpus; Nathaneal Reynolds; Heather A Behanna; Linda J Van Eldik; D Martin Watterson
Journal:  J Neuroimmunol       Date:  2008-10-15       Impact factor: 3.478

Review 7.  Monoclonal antibody therapy in experimental allergic encephalomyelitis and multiple sclerosis.

Authors:  Xu Zhang; Raymond Hupperts; Marc De Baets
Journal:  Immunol Res       Date:  2003       Impact factor: 2.829

8.  Swift entry of myelin-specific T lymphocytes into the central nervous system in spontaneous autoimmune encephalomyelitis.

Authors:  Gláucia C Furtado; Maria Cecilia G Marcondes; Jo-Ann Latkowski; Julia Tsai; Allen Wensky; Juan J Lafaille
Journal:  J Immunol       Date:  2008-10-01       Impact factor: 5.422

9.  T lymphocytes do not directly mediate the protective effect of estrogen on experimental autoimmune encephalomyelitis.

Authors:  Magdalena J Polanczyk; Richard E Jones; Sandhya Subramanian; Michael Afentoulis; Cathleen Rich; Melissa Zakroczymski; Paul Cooke; Arthur A Vandenbark; Halina Offner
Journal:  Am J Pathol       Date:  2004-12       Impact factor: 4.307

10.  Perturbation of chemokine networks by gene deletion alters the reinforcing actions of ethanol.

Authors:  Yuri A Blednov; Susan E Bergeson; Danielle Walker; Vania M M Ferreira; William A Kuziel; R Adron Harris
Journal:  Behav Brain Res       Date:  2005-08-18       Impact factor: 3.332

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.